VIDAZA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VIDAZA (VIDAZA).
Azacitidine is a pyrimidine nucleoside analog of cytidine that inhibits DNA methyltransferase, causing hypomethylation of DNA and direct cytotoxicity in abnormal hematopoietic cells.
| Metabolism | Primarily metabolized by cytidine deaminase and possibly by deamination; not significantly metabolized by CYP450 enzymes. |
| Excretion | Renal: 50-85% as unchanged drug and metabolites; biliary/fecal: minimal (<10%) |
| Half-life | Terminal half-life: 5-7 hours (subcutaneous); 3-5 hours (intravenous); supports 7-day dosing cycle |
| Protein binding | Approximately 80-90% bound to human plasma proteins |
| Volume of Distribution | Vd: 4.5-8.9 L/kg; indicates extensive tissue distribution |
| Bioavailability | Subcutaneous: ~89% (relative to intravenous) |
| Onset of Action | Subcutaneous: Clinical effect (hematologic improvement) within 1-3 cycles (4-12 weeks); Intravenous: similar |
| Duration of Action | Duration of demethylation effect: ~2-4 weeks post-treatment; dosing cycle: 7 days of 28-day cycle |
75 mg/m2 subcutaneously or intravenously once daily for 7 days every 4 weeks.
| Dosage form | POWDER |
| Renal impairment | For serum creatinine >2 mg/dL or BUN >50 mg/dL, reduce dose to 50% of starting dose. For end-stage renal disease (GFR <15 mL/min/1.73 m2) not on dialysis, use with caution and monitor toxicity. |
| Liver impairment | No specific dose adjustment recommended for hepatic impairment. Use with caution in severe hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; no standard pediatric dosing available. |
| Geriatric use | No specific dose adjustment required. Monitor for renal function and increased sensitivity to myelotoxicity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VIDAZA (VIDAZA).
| Breastfeeding | It is not known whether azacitidine is excreted in human breast milk. Due to the potential for serious adverse effects in the nursing infant, breastfeeding is not recommended during treatment and for at least 1 week after the last dose. The M/P ratio is unknown. |
| Teratogenic Risk | Azacitidine is a nucleoside analog that inhibits DNA methylation and is teratogenic in animals. Based on its mechanism of action, there is a potential risk of teratogenicity in humans. Limited human data exist. The drug should be avoided during pregnancy, especially in the first trimester, due to the risk of fetal malformations. In later trimesters, there may be risks of growth restriction and other adverse effects. Pregnancy testing is recommended before initiation. |
■ FDA Black Box Warning
VIDAZA is contraindicated in patients with advanced malignant hepatic tumors. Use in patients with liver disease is associated with fatal hepatic coma.
| Serious Effects |
["Advanced malignant hepatic tumors","Known hypersensitivity to azacitidine or mannitol"]
| Precautions | ["Hepatotoxicity: Fatal hepatic coma may occur in patients with severe preexisting hepatic impairment.","Renal toxicity: Renal impairment may lead to increased toxicity; monitor renal function.","Hematologic toxicity: May cause severe neutropenia, thrombocytopenia, and anemia; monitor blood counts.","Tumor lysis syndrome: Risk in patients with high tumor burden.","Embryo-fetal toxicity: Can cause fetal harm."] |
Loading safety data…
| Fetal Monitoring | Monitor complete blood count with differential, liver function tests, serum creatinine, and electrolytes regularly. Due to risk of tumor lysis syndrome, monitor uric acid, potassium, phosphate, and calcium. Perform pregnancy testing before starting therapy in women of reproductive potential. Fetal monitoring (ultrasound) may be considered if exposure occurs during pregnancy. |
| Fertility Effects | Azacitidine may impair fertility in both males and females based on animal studies. In humans, it can cause amenorrhea and spermatogenic arrest. Gonadal suppression may occur. Advise patients about fertility preservation options before treatment. |